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The abnormality of DNA methylation is involved in tumour progression, and thus has a modulating effect on clinical outcome of
cancer patients. In this study, we measured the mRNA expression levels of three methylation-regulating genes (DNMT1, DNMT3b,
and MBD2) in 148 tumour samples from patients with non-small cell lung cancer (NSCLC) using quantitative real-time polymerase
chain reaction and then determined their prognostic values. Our data showed that the high level of DNMT1 expression was
significantly associated with an increased risk of death in all NSCLC patients (hazard ratio (HR), 1.74; 95% confidence interval (95%
CI), 1.04–2.90). However, the high level of DNMT3b expression was significantly associated with poor prognosis only in young
patients (o65 years). The high level of MBD2 expression had a significantly reduced risk for death only in male patients and in
squamous cell lung carcinoma (SQLC) patients. All three combination groups with DNMT1 and DNMT3b, DNMT1 and MBD2 or
DNMT3b and MBD2 revealed significant combined effects in male patients and SQLC patients. Our results suggest that DNMT1,
DNMT3b, and MBD2 may play important roles in modulating NSCLC patient survival and thus be useful for identifying NSCLC
patients who would benefit most from aggressive therapy.
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The malignant transformation of human cells is usually driven by
the activation of oncogenes or the inactivation of tumour
suppressor genes, which can be caused by epigenetic events
(Barrett et al, 1986; Simons, 1995; Jones and Laird, 1999). DNA
methylation has been well documented as the major form of
epigenetic gene regulation (Shames et al, 2007). Furthermore, an
altered DNA methylation pattern is one of the most consistent
epigenetic hallmarks of human cancer (Baylin, 2005; Esteller, 2005;
Luczak and Jagodzinski, 2006). Usually, neoplastic cells simulta-
neously exhibit global genomic hypomethylation and region-
specific hypermethylation. Most hypomethylation events in cancer
cells appear to occur in repetitive and parasitic elements, which are
heavily methylated in normal cells (Hoffmann and Schulz, 2005).
These events may result in increased genomic instability. The
hypermethylation of CpG islands in the promoter region of genes
has been reported to cause the inactivation of tumour suppressor
genes, which is critical to the process of tumorigenesis (Newell-
Price et al, 2000; Teodoridis et al, 2004; McCabe and Caudill, 2005).
The exact nature of the defect in methylation machinery of
tumour cells remain unclear; however, it may be related to the
expression of DNA methyltransferases (DNMTs), primarily
DNMT1, DNMT3a, and DNMT3b (Leonhardt and Bestor, 1993).
DNMTs usually catalyse the transfer of methyl groups to
CpG dinucleotides to produce either hemimethylated or fully
methylated DNA strands. DNMT1 is best known as the main-
tenance methyltransferase that copies methylation patterns after
DNA replication; DNMT3a and DNMT3b are primarily de novo
methylators of CpG sites. Numerous studies (Issa et al, 1993;
Robertson et al, 1999) have evaluated the expression of DNMTsi n
tumour tissue, and most have reported variable levels of over-
expression, particularly of DNMT1 and DNMT3b. Rhee et al (2002)
demonstrated that DNMT1 and DNMT3b cooperatively maintain
DNA methylation and gene silencing in human cancer cells. In
contrast, DNA demethylase-methyl-CpG-binding domain 2
(MBD2) performs the reverse reaction to DNMTs (Bhattacharya
et al, 1999). Compared to the adjacent normal tissue, a significant
decrease in MBD2 mRNA expression has been observed in various
tumour tissue types (Kanai et al, 1999; Patra et al, 2002). These
findings suggest that DNA methyltransferases and DNA demethy-
lases play pivotal roles in the initiation and progression of tumours
and thus may be useful in the clinical diagnosis and prognostic
assessment of cancer.
Lung cancer is the leading cause of cancer-related death in the
United States, with an estimated 160390 deaths in 2007 (Jemal
et al, 2007). The most common histological type is non-small cell
lung cancer. The current 5-year survival rate of non-small cell lung
cancer (NSCLC) is only 2–47% for different stages, and this has
improved little over the past two decades. Thus, new prognostic
markers are needed to help identify patients with poor prognoses,
who may benefit from more aggressive treatment approaches.
Previous studies have consistently reported that DNMT isoforms
are significantly upregulated in human lung cancer cell lines and
NSCLC tissue specimens (Sato et al, 2002; Vallbohmer et al, 2006).
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sHowever, studies of the association between DNMT expression and
clinical outcome in NSCLC patients have produced inconsistent
results (Kim et al, 2006; Vallbohmer et al, 2006; Lin et al, 2007),
and few have evaluated the prognostic value of MBD2. Therefore,
we determined the expression of DNMT1, DNMT3b, and MBD2 by
real-time quantitative PCR in 148 tumour samples from NSCLC
patients and analysed their prognostic value, both separately and
jointly.
MATERIALS AND METHODS
Patients and tissue specimens
One hundred forty-eight patients with histologically confirmed
NSCLC were included in this study, all of whom were recruited
from 1993 to 1997 and had undergone curative surgical resections
at The University of Texas MD Anderson Cancer Center. There
were no age, sex, ethnicity, or tumour stage restrictions on patient
enrolment. Fresh tumour tissues were frozen immediately after
excision and stored in liquid nitrogen until they were used for
RNA extraction. Demographic and clinical data were collected
from the patient history database and chart review at MD
Anderson Cancer Center. The survival duration was evaluated as
of June 2005. Study approval was obtained from the MD Anderson
institutional review board.
RNA extraction and cDNA synthesis
Total RNA extraction and cDNA synthesis were performed as
previously described (Lin et al, 2006). In brief, frozen tissues were
homogenised, and total RNA was isolated with the EZNA total
RNA kit (Omega Bio-tek, Doraville, GA, USA) according to the
manufacturer’s instructions. RNA was eluted in RNase-free water,
and the concentration was determined by spectrophotometer
(Beckman Coulter, Fullerton, CA, USA). The quality of RNA
samples was determined by 1% agarose gel electrophoresis and
ethidium bromide-staining. The cDNA synthesis reaction was then
carried out using the Taqman reverse transcription reagents kit
(Applied Biosystems, Branchburg, NJ, USA) in a final volume of
20ml containing 1  RT buffer, 5mmoll
 1 MgCl2, 250mmoll
 1
each dNTP, 20 units of RNase inhibitor, 50 units of multiscribe
reverse transcriptase, 2.5mmoll
 1 random hexamers, and 0.5mgo f
total RNA. The reaction mixtures were incubated at ambient
temperature for 10min and then at 421C for 30min. Reverse
transcriptase was inactivated by heating at 991C for 5min. All
cDNA products were stored at  301C until they were used for the
real-time PCR.
Real-time PCR
The primers and probes for real-time PCR were designed using
Primer Express software (version 2.0, Applied Biosystems). We
confirmed the specificity of primers and probes and the absence of
single nucleotide polymorphisms by searching the Genebank
database. To avoid amplifying residual genomic DNA, one of the
two primers or the probe was designed across the junction region
between two exons. The sequences of the primers and probes were
as follows: DNMT1, forward primer (FP): 5-AGAAGAGACGTAGA
GTTACATCCAGAGA-3, reverse primer (RP): 5-GCGTTCCTGATT
TTGCTCTTTC-3, probe: 5-FAM- CGAGTTGCTAGACCGCTTCCT
GC AGA-TAMRA-3; DNMT3b, FP: 5-CGCACCCCGGAGATCA-3,
RP: 5-ACTGGACACCTCCC TCTTGGA-3, probe: 5-FAM-AGGCCG
AAGATCAAGCTCGCGACT-TAMRA-3; MBD2, FP: 5-AGTGAAAT
CAGACCCACAACGA-3, RP: 5-GCACTAAGTCCT TGTAGCCTCTT
CTC-3, probe: 5-FAM-TGAATGAACAGCCACGTCAGCTTTTCTA
TAMRA-3; and GAPDH, FP: 5-AAGGCTGAGAACGGGAAGC-3,
RP: 5-GAGGGATCTCGC TCCTGGA-3, probe: 5-FAM-TGTCATCA
ATGGAAATCCCATCACCATC-TAMRA-3.
PCR amplification and real-time detection of product were
performed using the ABI Prism 7900 sequence detection system
(Applied Biosystems) in a 10-ml reaction mixture consisting of 1 
Taqman buffer A, 3.4mM MgCl2, 100mM each dNTP, 0.2mM each
primer, 0.1mM probe, 0.02U of AmpliTaq Gold DNA polymerase,
and 1ml of each synthesized cDNA template. The thermal cycling
conditions comprised one cycle at 951C for 10min and 40 cycles at
951C for 15s, 601C for 1min. A relative quantification method
using standard curve was used to measure the relative expression
levels of each gene in all samples. In brief, the cDNA product of
commercial human total RNA (Stratagene, La Jolla, CA, USA) was
serially diluted by fivefold per dilution to produce a 6-point
standard curve for each tested gene. The quantity of tested gene in
each sample was arbitrarily measured as the dilution level of
standard sample. The human GAPDH gene was used as an internal
control to normalise the RNA input amount, reverse transcription
efficiency, and RNA quality. The relative expression levels of each
sample were expressed as N-fold expression differences in the
target gene relative to the GAPDH genes. The PCR reaction for
each sample was duplicated, and the mean value was used in the
statistical analysis.
Statistical analysis
We used STATA statistical software, version 8.0 (Stata Corp.,
College Station, TX, USA), for all statistical analyses. Smoking
status and pack-years were categorised as previously described
(Wu et al, 2003). Overall survival duration was defined as the time
from lung cancer diagnosis to the date of patient death or last
follow-up. Survival status was evaluated using Pearson’s w
2 test or
Fisher’s exact test for categorical variables and Student’s t-test for
continuous variables. The expression levels of all three genes were
dichotomised as high or low, with the median values of normalised
mRNA expression used as the cutoff points. The hazard ratios and
95% confidence intervals were calculated using Cox proportional
hazards regression analysis to determine the effects of gene
expression level on overall survival. Multivariate analysis was used
to control potential confounding factors (age, sex, ethnicity,
smoking status, tumour grade, and clinical disease stage). Kaplan–
Meier plots and the log-rank test were used to evaluate the
association between survival duration and the expression of the
three genes. Because only three genes were involved in our study,
multiple testing issues have not been considered for our analysis.
All reported P-values were based on two-sided tests, and the level
of significance was set at Po0.05.
RESULTS
Distribution of demographic and clinical variables
Patients’ demographic and clinical characteristics are summarised
in Table 1. One hundred forty-eight NSCLC patients were included
in this study, with a mean age of 65.0 years. Ninety-four percent of
patients were white, and 92% were ever smokers. The most
common histologic tumour types were lung adenocarcinoma
(47%) and SQLC (36%). Forty-eight percent of patients were at
stage I, 15% at stage II, 23% at stage III and 14% unknown.
However, tumours were mostly at intermediate (grade 2 (38.5%))
or low (grade 3 (39%)) differentiations. The median survival
duration was 45.9 months, and the 5-year overall survival rate was
42%. Among 136 patients with complete treatment information, 77
(57%) patients received surgery alone and 59 (43%) patients
received surgery with adjuvant chemo or radiotherapy. As shown
in Table 1, there were no significant differences in the age
(P¼0.16), sex (P¼0.22), ethnicity (P¼0.54), smoking
status (P¼0.42), pack-years (P¼0.66), or histologic tumour
subtype (P¼0.79) between patients who were alive and dead at
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significant risk predictor for death (Po0.001) in all patients,
followed by high grade (P¼0.09). In addition, when we compare
patients with surgery alone, patients with adjuvant therapy had a
significantly higher death rate (Po0.001), mainly because adjuvant
therapy, as a secondary treatment, was mostly applied to patients
of high stages and at high risks of recurrence and metastasis.
Association between DNMT1, DNMT3b, and MBD2
expression and overall survival
The median expression values for DNMT1, DNMT3b, and MBD2
genes are 1.363, 39.425 and 2.978, respectively. No significant
correlation was observed between the mRNA expression of
DNMT1, DNMT3b, and MBD2 and the tumour grade, stage, and
histological type (data not shown). We dichotomised the expres-
sion level of these three genes into high and low groups by using
the median value as the cutoff. According to the results of the
multivariate Cox proportional hazards model, DNMT1 expression
was significantly associated with patient survival rate of NSCLS
patients. After adjusting for age, sex, ethnicity, smoking status,
tumour grade, and clinical disease stage, we found that the high
level of DNMT1 expression was associated with a 74% increased
risk of death (HR, 1.74; 95% CI, 1.04–2.90). However, no
statistically significant association was found for DNMT3b (HR,
1.27; 95% CI, 0.78–2.06) and MBD2 (HR, 0.80; 95% CI, 0.48–1.35)
(Table 2). The Kaplan–Meier analysis revealed that patients with
the high level of DNMT1 expression had notably shorter median
survival duration (36.8 months) than did those with the low level
of expression (60.9 months) although it was not statistically
significant (P¼0.142, log-rank test) (Figure 1A). Moreover, we
found no significant difference between the median survival
durations of NSCLC patients with low and high levels of DNMT3b
or MBD2 expression (data not shown).
In stratified analyses (Table 2), our data showed that the high
level of DNMT1 expression was associated with a high risk of death
in male (HR, 2.17; 95% CI, 1.11–4.28) but not in females (HR,
1.63; 95% CI, 0.59–4.49), in heavy smokers (HR, 5.67; 95%
CI, 1.64–19.60) but not in light smokers (HR, 1.08; 95% CI,
0.54–2.19), and in SQLC patients (HR, 3.26; 95% CI, 1.22–8.70)
but not in adenocarcinoma patients (HR, 1.47; 95% CI, 0.64–3.37).
The Kaplan–Meier analyses (Figure 1B–D) also showed that,
compared with the low level of DNMT1 expression, the high level
of expression was only notably associated with short median
survival duration in males (35.7 vs 60.9 months, P¼0.102), in
heavy smokers (31.1 vs 61.3 months, P¼0.022), and in SQLC
patients (31.1 vs 69.0 months, P¼0.004). Furthermore, a high level
of DNMT3b expression was significantly associated with poor
prognosis in patients aged o65 years (HR, 2.76; 95% CI, 1.12–6.76).
In comparison, a high level of MBD2 expression provided
significant protective effect in male patients (HR, 0.40; 95% CI,
0.17–0.94) and SQLC patients (HR, 0.35; 95% CI, 0.12–1.03). The
Kaplan–Meier analyses for DNMT3b and MBD2 expressions
indicated the similar results (data not shown). In addition, we
performed stratified analysis of the three genes by adjuvant
therapy (Table 2). We didn’t find any notable effects of adjuvant
therapy on the prognostic values of three genes expression.
Combined analysis on the prognostic value of DNMT1,
DNMT3b, and MBD2 in different subgroups
On the basis of our initial findings, we defined high expression of
DNMT1 and DNMT3b and low expression of MBD2 as three
unfavourable factors that were associated with poor survival. We
determined the combined effect of either two genes on overall
survival in different subgroups of patients stratified by age, sex and
histological type (Table 3). All three combination groups with
DNMT1 and DNMT3b, DNMT1 and MBD2 or DNMT3b and MBD2
revealed significant combined effects in male patients (P for
trend¼0.023, o0.001 and ¼0.010, respectively) and SQLC
patients (P for trend¼0.022, 0.003 and 0.019, respectively), but
not in female patients (P for trend¼0.357, 0.243 and 0.341,
respectively) and adenocarcinoma patients (P for trend¼0.245,
0.487 and 0.431, respectively). Findings from Kaplan–Meier
analyses for all three combination groups also indicated that the
median overall survival duration was substantially declined as the
number of unfavourable factors increased in male patients and
SQLC patients but not in female patients and adenocarcinoma
patients (data not shown). In comparison, we found that age
exerted different effects on the prognostic value of three
combination groups.
DISCUSSION
In this study, we measured the mRNA expression level of three
methylation-related genes (DNMT1, DNMT3b and MBD2) in
NSCLC tumour tissues using quantitative real-time PCR and
evaluated their prognostic values. Our data showed that these three
Table 1 Distribution of demographic and clinical variables by survival
status
Alive Death
(n¼49) (n¼99)
Variable Number (%) Number (%) P-value
Gender
Male 24 (49) 59 (60)
Female 25 (51) 40 (40) 0.22
Ethnicity
Caucasian 45 (92) 94 (95)
Mexican American 1 (2) 2 (2)
African American 2 (4) 3 (3)
Others 1 (2) 0 (0) 0.54
Smoking status
a
Never smoker 6 (13) 6 (6)
Former smoker 17 (38) 36 (40)
Current smoker 22 (49) 49 (54) 0.42
Histology
Adenocarcinoma 23 (47) 46 (46)
SQLC 19 (39) 34 (34)
Other 7 (14) 19 (20) 0.79
Tumour stage
a
I 33 (79) 38 (45)
II 5 (12) 17 (20)
III 4 (10) 30 (35) o0.001
Grade
a
I 7 (18) 5 (6)
II 16 (41) 41 (46)
III 16 (41) 42 (48) 0.09
Treatment
Surgery alone 35 (45) 42 (55)
Surgery with adjuvant therapy 9 (15) 50 (85) o0.001
Age in years (mean±s.d.) 63.3±10.5 65.9±10.8 0.16
Pack-years
b (mean±s.d.) 50.1±33.0 52.6±24.7 0.66
aFew patients did not have documented smoking status, stage or grade information at
the time of this investigation.
bFor ever smokers only
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patients.
We found that the high level of DNMT1 expression was
significantly associated with poor overall survival in NSCLC
patients, independent of tumour stage and grade. Kim et al
(2006) reported similar results in a study of 102 NSCLC patients
(HR 3.51; 95% CI, 1.18–12.76). Lin et al (2007) further verified the
association between the high level of DNMT1 expression and poor
prognosis of lung cancer at protein level. In a mouse model of
prostate cancer, McCabe et al (2006) also found an association
between DNMT1 and survival and demonstrated that treatment
with 5-aza, a DNA methyltransferase inhibitor, prevented the
development of lymph node metastases and dramatically improved
survival. However, in a study of 91 NSCLC patients, no association
was found between DNMT1 mRNA expression and clinical
outcome (Vallbohmer et al, 2006). This discrepancy may be a
result of different patient populations and different methods for
normalisation of mRNA expression.
The molecular mechanism of DNMT1 survival modulation
remains to be elucidated. Several previous studies (Paz et al, 2003;
Robert et al, 2003) have suggested that DNMT1, as a major
methylation-inducing factor, is needed to maintain CpG methyla-
tion and aberrant gene silencing in human cancer cells. Kim et al
(2006) found that elevated mRNA levels of DNMT1 were
significantly associated with promoter hypermethylation of
tumour suppressor gene p16 in NSCLC patients. Lin et al (2007)
demonstrated that DNMT1 overexpression was associated with the
hypermethylation of FHIT, p16
ink4a, and RARb and that the
promoters of methylated FHIT, p16
ink4a, and RARb were bound by
DNMT1 protein. These findings suggest that DNMT1 hypermethylates
survival-associated tumour suppressor genes, leading to their
functional inactivation. However, a recent report (Sato et al,
2002) found no significant association between DNMT1 expression
and DNA methylation of some tumour-associated genes,
suggesting that DNMT1 also contributes to cancer development
and progression through alternative pathways. For example,
Table 2 Association of DNMT1, DNMT3b and MBD2 mRNA expression in tumour tissues with NSCLC patient survival
DNMT1
a DNMT3b
a MBD2
a
MRNA expression
b Alive Dead HR
c (95% CI) Alive Dead HR
c (95% CI) Alive Dead HR
c(95% CI)
Overall
Low 26 45 ref. 25 46 ref. 21 50 ref.
High 20 52 1.74 (1.04–2.90) 21 51 1.27 (0.78–2.06) 25 47 0.80 (0.48–1.35)
Age
d
o65 years
Low 12 18 ref. 15 17 ref. 10 24 ref.
High 9 24 3.08 (1.26–7.51) 6 25 2.76 (1.12–6.76) 11 18 1.40 (0.46–4.23)
X65 years
Low 13 27 ref. 9 29 ref. 10 26 ref.
High 10 28 2.23 (1.09–4.55) 14 26 0.74 (0.37–1.48) 13 29 0.66 (0.33–1.30)
Sex
Male
Low 16 27 ref. 14 27 ref. 10 30 ref.
High 6 30 2.17 (1.11–4.28) 8 30 1.63 (0.82–3.24) 12 27 0.40 (0.17–0.94)
Female
Low 10 18 ref. 11 19 ref. 11 20 ref.
High 14 22 1.63 (0.59–4.49) 13 21 1.29 (0.53–3.15) 13 20 0.86 (0.34–2.14)
Pack-years
e
o52
Low 14 26 ref. 10 20 ref. 10 25 ref.
High 9 23 1.08 (0.54–2.19) 13 29 1.02 (0.51–2.03) 13 24 0.72 (0.34–1.50)
X52
Low 8 13 ref. 9 15 ref. 7 19 ref.
High 2 15 5.67 (1.64–19.6) 1 13 1.60 (0.57–4.47) 3 9 0.66 (0.14–3.15)
Treatment
e
Surgery alone
Low 16 22 ref. 18 26 ref. 14 21 ref.
High 16 19 1.64 (0.71–3.77) 414 159 0.73 (0.31–1.70) 18 20 0.72 (0.29–1.77)
Surgery and adjuvant therapy
Low 7 21 ref. 4 18 ref. 5 26 ref.
High 2 29 2.16 (0.97–4.84) 5 32 1.22 (0.63–2.38) 4 24 0.84 (0.37–1.93)
Histology
Adenocarcinoma
Low 9 16 ref. 11 21 ref. 8 22 ref.
High 13 29 1.47 (0.64–3.37) 11 24 1.48 (0.72–3.04) 14 23 1.21 (0.43–3.43)
SQLC
Low 16 18 ref. 12 15 ref. 11 19 ref.
High 2 15 3.26 (1.22–8.70) 6 18 1.56 (0.58–4.24) 7 14 0.35 (0.12–1.03)
aNumber of patients may not add up to the total number due to assay failure.
bDichotomised using the median value for mRNA expression in tumour tissues. The cutoff points
for DNMT1, DNMT3b, and MBD2 were 1.362, 39.425 and 2.978, respectively.
cAdjusted for age, sex, ethnicity, smoking status, tumour grade and clinical disease stage when
appropriate.
dDichotomised using the median value in all patients.
eDichotomised using the median value in ever smokers.
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proliferating cell nuclear antigen, a factor that assists in DNA
replication, suggesting that DNMT1 may play a vital role in
replication except for regulating gene expression. Egger et al
(2006) also demonstrated that DNMT1 is essential to the
proliferation and survival of cancer cells. In addition, Biniszkiewicz
et al (2002) reported that the overexpression of DNMT1 resulted
in the activation of silent alleles in Igf2 gene by de novo
methylation, thus leading to increased cell proliferation and
overgrowth.
We found no significant association between DNMT3b
expression and survival in all NSCLC patients. This result is
consistent with those of Kim et al (2006) and Vallbohmer et al
(2006). However, possibly because of a limited number of samples,
neither of these studies included an analysis stratified by patient
characteristics. Our stratified data analysis revealed a significant
association between the high level of DNMT3b expression and
increased risk of death in patients aged o65 years, suggesting that
DNMT3b expression may be an age-related prognostic predictor.
Similarly, Girault et al (2003) found that DNMT3b overexpression
was associated with a short relapse-free survival duration in a
subgroup of breast cancer patients, and Wang et al (2004)
demonstrated that increased DNMT3b promoter activity (resulting
from a C-to-T polymorphism) led to lower survival duration in
patients with SQLC of the head and neck. The functional
mechanism of DNMT3b in prognosis is still unclear. Unlike
DNMT1, DNMT3b has been suggested to be site-selective in the
regulation of aberrant gene silencing. DNMT3b expression has also
been found to be essential for cancer cell survival by inhibiting
apoptosis of tumour cells but not normal cells (Beaulieu et al,
2002). The results of in vitro studies by Geiman et al (2004) further
indicate that DNMT3b contributes to gene silencing by recruiting
chromatin remodeling histone deacetylase.
In this study, we also found that the high level of MBD2
expression was associated with a significant protective effect in
male patients (HR, 0.40; 95% CI, 0.17–0.94) and SQLC patients
(HR, 0.35; 95% CI, 0.12–1.03). MBD2 has been found to catalyse
demethylation by directly removing methyl groups from 5-
methylcytosine residues in DNA (Bhattacharya et al, 1999). The
results of our previous study (Zhu et al, 2004) suggest that MBD2
expression prevents age-related, sex-related, and smoking-induced
hypermethylation. Several studies have demonstrated altered
MBD2 mRNA expression in various tumour tissue specimens,
but the findings have been inconsistent. A significant reduction in
the level of MBD2 mRNA expression was found in human
colorectal and gastric tissues compared with nonmalignant tissues
(Kanai et al, 1999), whereas elevated expression was reported in
breast cancer (Billard et al, 2002). These differences may be
explained by MBD2’s dual functions (transcription repression and
demethylation). To date, the specific role of MBD2 in NSCLC
remains to be determined. In the present study, NSCLC tumour
tissues had significantly lower levels of MBD2 expression than did
adjacent normal tissues (data not shown), suggesting that the effect
of MBD2 expression on clinical outcome may be related to
demethylation. However, more conclusive evidence is needed.
Methylation varies as a function of age, sex, and smoking status
(Ahuja and Issa, 2000; Toyooka et al, 2003). Therefore, it is
plausible for our study to indicate that age, gender and smoking
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Figure 1 Kaplan–Meier survival estimates for patients with NSCLC. Survival duration by DNMT1 expression (A) in all patients, (B) in male patients, (C)
in patients who were heavy smokers and (D) in SQLC patients; MSD, Median survival duration.
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smay modify the prognostic value of methylation-related genes in
NSCLC patients. In addition, histologic tumour type-related
differences in methylation have been documented in many
genes, particularly tumour suppressor genes (Kim et al, 2004).
Accordingly, our data revealed a histology-related prognostic
significance of DNMT1 and MBD2 expression in NSCLC patients.
To comprehensively evaluate the prognostic value of DNMT1,
DNMT3b, and MBD2, we performed a combined analysis. Our
results suggest that these genes may be useful for determining
prognosis in NSCLC patients, particularly in male patients and
SQLC patients. Nevertheless, the results of our stratified and
combined analyses should be interpreted cautiously because of the
small sample size in each stratum and empirical cutoff point
chooses. A larger study is needed to verify these findings.
To conclude, our findings further clarify the inconsistent
findings of previous reports. We found that elevated DNMT1
mRNA expression was significantly associated with poor prognosis
in NSCLC patients. DNMT3b and MBD2 had potential age-, sex-,
and histology-related prognostic value in NSCLC patients,
respectively. In addition, there is a significant combined effect of
these three genes on overall survival. Therefore, these three genes
could be useful in predicting clinical outcome in NSCLC patients
and thus identifying patients who would benefit from aggressive
therapy.
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